Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) EBITDA Margin (2016 - 2025)

Protalix BioTherapeutics has reported EBITDA Margin over the past 16 years, most recently at 0.56% for Q4 2025.

  • Quarterly results put EBITDA Margin at 0.56% for Q4 2025, down 2413.0% from a year ago — trailing twelve months through Dec 2025 was 0.11% (down 358.0% YoY), and the annual figure for FY2025 was 0.54%, down 353.0%.
  • EBITDA Margin for Q4 2025 was 0.56% at Protalix BioTherapeutics, down from 14.02% in the prior quarter.
  • Over the last five years, EBITDA Margin for PLX hit a ceiling of 58.22% in Q2 2023 and a floor of 142.62% in Q2 2021.
  • Median EBITDA Margin over the past 5 years was 20.14% (2022), compared with a mean of 30.92%.
  • Biggest five-year swings in EBITDA Margin: crashed -12219bps in 2021 and later skyrocketed 16083bps in 2024.
  • Protalix BioTherapeutics' EBITDA Margin stood at 66.74% in 2021, then soared by 57bps to 28.95% in 2022, then tumbled by -370bps to 136.14% in 2023, then surged by 118bps to 24.69% in 2024, then tumbled by -98bps to 0.56% in 2025.
  • The last three reported values for EBITDA Margin were 0.56% (Q4 2025), 14.02% (Q3 2025), and 9.78% (Q2 2025) per Business Quant data.